Cipla, Novartis Onbrez Duel Heading For Compulsory License?

In what it termed as a balancing act, the Delhi High Court blocked Cipla from making and marketing copies of Novartis’ respiratory brand Onbrez in India while keeping options open for the Indian company to explore a compulsory license. A resolution is far from sight. In its 143-page detailed verdict, the court delved into several approaches to reach an amicable settlement including payment of royalty, but the main case revolving around alleged infringement of the patent will continue to be heard.